SUCAMPO PHARMACEUTICALS, INC. Accumulated Other Comprehensive Income
SUCAMPO PHARMACEUTICALS, INC. had Accumulated Other Comprehensive Income of $54.46 million as of 2017-09-30, per its 10-Q filed 2017-11-01.
Discontinued › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2017-11-01
- 2017-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $54.46M.
- 2017-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $54.43M.
- 2017-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $54.45M.
- 2016-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $54.53M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2017-09-30 | $54.46M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $54.43M 10-Q · filed 2017-08-02 |
| 2017-03-31 | $54.45M 10-Q · filed 2017-05-03 |
| 2016-12-31 | $54.53M 10-Q · filed 2017-11-01 |
| 2016-09-30 | $54.34M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $49.69M 10-Q · filed 2016-08-03 |
| 2016-03-31 | $28.96M 10-Q · filed 2017-05-03 |
| 2015-12-31 | $13.41M 10-Q · filed 2017-05-03 |
| 2015-09-30 | $14.41M 10-Q · filed 2015-11-04 |
| 2015-06-30 | $14.10M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $14.43M 10-Q · filed 2016-05-05 |
| 2014-12-31 | $14.27M 10-K · filed 2017-03-08 |
| 2014-09-30 | $15.64M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $15.36M 10-Q · filed 2014-08-06 |
| 2014-03-31 | $15.49M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $15.60M 10-K · filed 2017-03-08 |
| 2013-09-30 | $15.76M 10-Q · filed 2013-11-08 |
| 2013-06-30 | $16.00M 10-Q · filed 2013-08-09 |
| 2013-03-31 | $16.20M 10-Q · filed 2013-05-10 |
| 2012-12-31 | $16.17M 10-K/A · filed 2016-03-16 |
| 2012-09-30 | $16.11M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $16.26M 10-Q · filed 2012-08-09 |
| 2012-03-31 | $16.26M 10-Q · filed 2012-05-10 |
| 2011-12-31 | $17.85M 10-K · filed 2013-03-18 |
| 2011-09-30 | $17.84M 10-Q · filed 2011-11-09 |
| 2011-06-30 | $19.86M 10-Q · filed 2011-08-05 |
| 2010-12-31 | $16.57M 10-K · filed 2012-03-15 |